文献速递脑血管病神经重症与神经感染

肾功能损害对脑出血强化降压治疗及结局的影响:ATACH-2 结果

Impact of Renal Impairment on Intensive Blood-Pressure-Lowering Therapy and Outcomes in Intracerebral Hemorrhage: Results From ATACH-2.
PubMed 文献 · Neurology · 2021-07-01

本研究为 ATACH-2 试验的事后分析,纳入 974 例脑出血患者,按基线 eGFR 分组评估肾功能对 90 天死亡或残疾及强化降压疗效的影响。结果发现 eGFR<60 mL/min/1.73 m2 者结局更差,且该组强化降压与更高不良结局相关,交互作用显著。

要点

  • eGFR<60 mL/min/1.73 m2 的脑出血患者 90 天死亡或残疾风险增高。
  • 肾功能损害患者接受强化降压可能增加不良结局风险。
  • eGFR 可能用于识别强化降压高风险患者。

核心结论

  • eGFR 降低与脑出血后不良结局相关,且 eGFR 分组与降压治疗分配存在显著交互作用,提示肾功能损害患者强化降压存在安全性顾虑。

研究设计与样本

  • ATACH-2 随机、两组、开放标签试验的事后分析,共随机 1000 例,分析 974 例。

主要发现

  • 基线 eGFR 中位数 88(四分位距 68-99)mL/min/1.73 m2。
  • eGFR<60 mL/min/1.73 m2 者死亡或残疾调整 OR 2.02(95%CI 1.25-3.26),60-89 组 OR 1.01(95%CI 0.70-1.46)。
  • 强化降压组中 eGFR≥90、60-89、<60 的 OR 分别为 0.89(95%CI 0.55-1.44)、1.13(0.68-1.89)、3.60(1.47-8.80),交互作用 P=0.02。

临床怎么用

  • 脑出血患者评估基线 eGFR 有助于识别强化降压可能获益不佳或风险增高的人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The clinical effect of renal impairment on intracerebral hemorrhage (ICH) is unknown. This study sought to assess whether estimated glomerular filtration rate (eGFR) affects clinical outcomes or modifies the efficacy of intensive systolic blood pressure (BP) control (target, 110-139 mm Hg) against the standard (target, 140-179 mm Hg) among patients with ICH. METHODS: We conducted post hoc analyses of ATACH-2, a randomized, 2-group, open-label trial. The baseline eGFR of each eligible patient was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The outcome of interest was death or disability at 90 days. Multivariate logistic regression models were used for analysis. RESULTS: Among the 1,000 patients randomized, 974 were analyzed. The median baseline eGFR was 88 (interquartile range, 68, 99) mL/min/1.73 m2; 451 (46.3%), 363 (37.3%), and 160 (16.4%) patients had baseline eGFR values of ≥90, 60-89, and <60 mL/min/1.73 m2, respectively. Compared with normal eGFR (≥90 mL/min/1.73 m2), higher odds of death or disability were noted among those with eGFR values of <60 mL/min/1.73 m2 (adjusted odds ratio [OR], 2.02; 95% confidence interval [CI], 1.25-3.26) but not among those with eGFR values of 60-89 mL/min/1.73 m2 (OR, 1.01; 95% CI, 0.70-1.46). The odds of death or disability were significantly higher in the intensive arm among patients with decreased eGFR; the ORs were 0.89 (95% CI, 0.55-1.44), 1.13 (0.68-1.89), and 3.60 (1.47-8.80) in patients with eGFR values of ≥90, 60-89, and <60 mL/min/1.73 m2, respectively (p for interaction = 0.02). DISCUSSION: Decreased eGFR is associated with unfavorable outcomes following ICH. The statistically significant interaction between the eGFR group and treatment assignment raised safety concerns for the intensive BP-lowering therapy among patients with renal impairment. TRIAL REGISTRATION INFORMATION: Clinicaltrials.gov identifier: NCT01176565. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in spontaneous ICH, decreased eGFR identifies patients at risk of death or disability following intensive BP control.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Fukuda-Doi M, Yamamoto H, Koga M, et al. Impact of Renal Impairment on Intensive Blood-Pressure-Lowering Therapy and Outcomes in Intracerebral Hemorrhage: Results From ATACH-2. Neurology. 2021. PMID: 34210824. doi:10.1212/WNL.0000000000012442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。